Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 18, Issue 12, pp. 2270-2282
PubMed
Published By
Print ISSN
Online ISSN
History
- Received April 12, 2019
- Revision received July 25, 2019
- Accepted August 27, 2019
- Published first September 4, 2019.
Article Versions
- Previous version (September 4, 2019 - 09:00).
- Previous version (September 5, 2019 - 07:13).
- Previous version (September 26, 2019 - 07:05).
- Previous version (November 21, 2019 - 06:57).
- You are viewing the most recent version of this article.
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Thinh H. Nguyen1,2,
- Balakrishna Koneru1,
- Sung-Jen Wei1,
- Wan Hsi Chen1,
- Monish Ram Makena1,
- Eduardo Urias1,
- Min H. Kang1,2, and
- C. Patrick Reynolds1,2,*
- 1Cancer Center, Departments of Pediatrics, Cell Biology & Biochemistry, and Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
- 2Department of Pharmacology and Neuroscience, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.
- ↵*Corresponding Author:
C. Patrick Reynolds, Texas Tech University Health Sciences Center School of Medicine, 3601 4th Street, STOP 9445, Lubbock, TX 79430-9445. E-mail: patrick.reynolds{at}ttuhsc.edu
December 2019
Volume 18, Issue 12
Volume 18, Issue 12
Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models
Jump to section
Advertisement